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Abstract
Background: The heterogeneity of endothelial cell types underlies their remarkable ability to sub-specialize and
provide specific requirements for a given vascular bed. Here, we compared rat microvascular endothelial cells
(MECs) derived from the brain and spinal cord in both basal and inflammatory conditions.
Methods: We used whole rat genome microarrays to compare, at different time points, basal and TNF-α-induced
gene expression of rat MECs from in vitro models of the blood-brain barrier (BBB) and blood-spinal cord barrier
(BSCB). Validation at both messenger RNA (mRNA) and protein levels was performed on freshly extracted microvessels
(MVs) from the brain and spinal cord (BMVs and SCMVs, respectively), as these were considered the closest in vivo
tissues to cultured MECs.
Results: Most of the genes encoding adhesion/tight junction molecules and known endothelial markers were similarly
expressed in brain and spinal cord MECs (BMECs and SCMECs, respectively). However, one striking finding was the
higher expression of several Hox genes, which encode transcription factors involved in positional identity. The
differential expression of Hoxa9 and Hoxb7 at the mRNA levels as well as protein levels was confirmed in BMVs
and SCMVs. Although the TNF-α response was in general higher in BMECs than in SCMECs at 12 h, the opposite
was observed at 48 h. Furthermore, we found that expression of Tnfrsf1a and Tnfrsf1b encoding the TNF receptor
super-family member 1a/TNFR1 and 1b/TNFR2, respectively, were constitutively higher in BMVs compared to SCMVs.
However, only Tnfrsf1b was induced in SCMECs in response to TNF-α at 24 and 48 h.
Conclusions: Our results support a role for HOX members in defining the positional identities of MECs in vivo. Our
data also suggest that the delayed transcriptional activation upon TNF-α treatment in SCMECs results from the
requirement of the TNF-induced expression of Tnfrsf1b. In contrast, its high basal expression in BMECs might be
sufficient to confer an immediate and efficient TNF-α response.
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Background
The brain and spinal cord are endowed with particular
vascular systems, known as the blood-brain barrier
(BBB) and blood-spinal cord barrier (BSCB), respect-
ively, which maintain homeostasis between nervous
parenchyma and peripheral circulation. These barriers
are composed of microvascular endothelial cells
(MECs) and neighboring elements of the neuro-glia-
vascular unit (NGVU) such as pericytes, astrocytic
end-feet processes, and neurons. The two vascular sys-
tems share physical and physiological barrier proper-
ties including basement membranes, highly
differentiated tight junctions (TJs), low levels of endo-
cytosis and vesicular transport, a broad spectrum of
molecular pumps, polarized carriers, and receptors in-
volved in transcytosis mechanisms [1, 2].
Despite these common features, the BSCB presents
structural and functional differences resulting in distinct
vulnerability to pathological insults when compared to
the BBB [2, 3]. For instance, the microvessels (MVs) of
the spinal cord contain glycogen deposits, which are not
normally seen in the cerebral MVs [4]. Only limited pop-
ulations of brain astrocytes express the phosphorylated
form of glial fibrillary acidic protein (GFAP) while almost
all astrocytes in the spinal cord do so [5]. Most in vivo
studies describe uniform presence of pericytes in various
brain regions, while the spinal cord presents with 70 % less
pericytes compared to the brain, with a non-uniform
distribution along the rostrocaudal extent of the spinal
cord, the thoracic region being richer in pericytes [6, 7]. In
vitro, brain and spinal cord pericytes differ markedly in
their potential for tube formation and migration,
reflecting more differences between the BBB and BSCB
[8]. Such differences in their microenvironment may in
turn induce MEC heterogeneity between brain and
spinal domains, correlating with a higher BSCB inher-
ent permeability [9, 10]. This increased permeability
might result from differences in cell junction protein
expression between BBB and BSCB endothelial cells. In
cultured SCMECs compared to BMECs, TJ proteins
ZO-1 and occludin expression levels are decreased,
while claudin-1 and claudin-5 remain unchanged, con-
firming that this decrease is specific [11]. Adherens
junction proteins such as VE-cadherin and β-catenin
also show reduced expression in SCMVs and cultured
SCMECs [11].
Like their brain counterparts, SCMECs are involved
in pathological processes associated with many neuro-
logical conditions [3]. Although, the structural and
functional differences might explain that certain disease
states differentially affect BMEC and SCMEC popula-
tions, very little is known concerning their intrinsic dif-
ferences, including their response to inflammation. To
gain more insight into such differences, a comparative
transcriptomic analysis was performed on RNAs extracted
from MEC monolayers of in vitro models of the BBB and




Procedures involving animals conform to National and
European regulations (EU directive No. 2010/63) and to
authorizations delivered to our animal facility (No. C13
055 08) and to the project (No. 00757.02) by the Local
Ethics Committee and French Ministry of Research. All
efforts were made to minimize animal suffering and
reduce the number of animals used. Wistar rats were
obtained from Elevage Janvier (St Berthevin, France).
Rat syngeneic in vitro BBB and BSCB models
The production of in vitro BBB and BSCB models is
based on our previously described protocol [12]. Briefly,
primary cultures of BMECs and SCMECs, prepared from
5- to 6-week-old Wistar rats, were seeded in the luminal
compartment of six-well plate polyethylene insert filters
(Merck Millipore, Billerica, MA, USA), pre-coated with
collagen type IV and fibronectin (BD Biosciences, Frank-
lin Lakes, NJ, USA) to establish the endothelial cell
monolayers. Astrocytes, prepared from neonatal Wistar
rats, were seeded in the bottom of the six-well plates
and co-cultured with the endothelial cell monolayers in
endothelial cell media (ECM) containing DMEM/F12
supplemented with 20 % bovine platelet poor plasma
derived serum (Alfa Aesar, Ward Hill, MA, USA), basic
fibroblast growth factor (bFGF) 2 ng/mL, heparin 100 μg/
mL, gentamycin 50 μg/mL, HEPES 2.5 mM, and hydrocor-
tisone 500 nM (all from Life Technologies, Carlsbad, CA,
USA). Under these conditions, the BMEC and SCMEC
monolayers differentiate, express junction-related proteins
within 3 days, and remain optimally differentiated during
three more days.
Induction and assessment of inflammation
Cytokine production
The day of the experiment, the inserts containing the
BMEC and SCMEC monolayers were transferred to new
six-well plates without astrocytes and stimulated for 12,
24, and 48 h with recombinant rat TNF-α 5 ng/mL
(Peprotech, Rocky Hill, NJ, USA). Supernatants were
collected, centrifuged, and stored at −80 °C until ana-
lysis. Rat CCL2 levels were evaluated using commercially
available ELISA kits (Peprotech) according to the manu-
facturer’s instructions. All samples were analyzed in
duplicates.
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Transport assay
After 24 h inflammation with recombinant rat TNF-α
(5 ng/mL, Peprotech), barrier integrity of the in vitro
models was controlled with Lucifer Yellow (LY CH lithium
salt, Sigma Aldrich), a small hydrophilic molecule (MW
457 g/mol) retained by the monolayers as previously de-
scribed [12]. Briefly, quantification of the LY paracellular
leakage from the luminal to the abluminal compartment
was assessed by fluorimetric analysis (excitation at 430 nm
and emission at 535 nm) and expressed in LY permeabil-
ity, Pe(LY). Barrier integrity was validated for Pe(LY) below
0.6.10−3 cm/min.
Immunocytochemistry
The MEC monolayers were washed three times with
PBS 1× (Life Technologies) and gently dissociated
from the insert filters followed by a 20-min fixation in
paraformaldehyde (PFA) 4 % (w/v) (Sigma Aldrich,
Saint-Louis, MO, USA) prior to immunocytochemistry.
After three washes with PBS 1× (Life Technologies), the
cells were pre-incubated for 30 min at room temperature
(RT) with blocking buffer containing BSA 3 % (PAA
Laboratories, Velizy-Villacoublay, France) in PBS 1×.
The MEC monolayers were stained for 1 h in PBS 1×
containing BSA 1 % (PAA Laboratories), with saponine
0.1 % (Sigma Aldrich) for membrane permeabilization,
with a rabbit anti-occludin 1.5 μg/mL (Life Technologies).
Cell nuclei were labeled with Hoechst 33342 1/1000 (Life
Technologies) in co-incubation with a donkey anti-rabbit
Alexa Fluor 488 secondary antibody (Jackson Immunore-
search, West Grove, PA, USA). Cells were washed and
mounted in Prolong Gold antifade mounting medium
(Life Technologies). The mounted slides were observed
with a Leica TCS SP2 confocal microscope (Leica
Microsystems, Heidelberg, Germany). High-magnification
images were acquired using a 63X HCX PL APO oil
immersion objective and analyzed using the NIH ImageJ
software (version 1.49o for Mac).
Tissue sampling
The BMEC and SCMEC monolayers (stimulated or
not with TNF-α) were pre-incubated on ice with a so-
lution of DPBS 1× (without calcium and magnesium)
and EDTA 0.25 mM (both from Life Technologies),
then mechanically detached with a cell scraper and
centrifuged at 1200×g for 10 min. The BMVs and
SCMVs were prepared from 5- to 6-week-old Wistar
rats according to our previously described protocol
[12]. Instead of plating, they were washed with DPBS
1× (Life Technologies) and centrifuged at 1200×g for
10 min. All samples were snap-frozen in liquid nitro-
gen for later use or mechanically dissociated in RIPA
buffer (Sigma Aldrich), called lysates (Lt), for western
blot analysis.
RNA isolation
Total RNA was isolated from frozen BMEC and SCMEC
monolayers or BMVs and SCMVs using the RNeasy
plus Universal Mini kit (Qiagen, Courtaboeuf, France),
according to the manufacturer’s instructions. RNA con-
centration was determined using a Nanodrop 2000
spectrophotometer (ThermoFisher Scientific, Villebon
sur Yvette, France) and RNA integrity assessed on an
Agilent 2100 Bioanalyzer (Agilent Technologies, Les
Ulis, France).
Microarray assay
The transcriptome analysis of BMEC and SCMEC
monolayers (stimulated or not with TNF-α) was per-
formed on rat Whole Genome Oligo Microarrays;
40,000 genes (Agilent Technologies). Sample amplifi-
cation, labeling, and hybridization were performed in
line with the Agilent one-color microarray-base ana-
lysis (low input quick amp labeling) protocol (Agilent
Technologies). Briefly, total RNA was reverse tran-
scribed into complementary DNA (cDNA) using the
T7 promoter primer. Synthesis of cyanine-3-labeled
complementary RNA (cRNA) from cDNA was per-
formed in a solution containing dNTP mix, T7 RNA
polymerase, and cyanine 3-dCTP and then incubated
at 40 °C for 2 h. Labeled cRNA was purified and frag-
mented before hybridization on Agilent Rat Gene Ex-
pression 4X44K Arrays (Agilent Technologies, ref:
G4131F) at 65 °C for 17 h. Raw microarray signals
were scanned and extracted using Agilent Feature Ex-
traction Software (Agilent Technologies). AgiNDR
package was used for quality control and normalization.
Quantile methods and a background correction were ap-
plied for data normalization. Microarray data are available
in the ArrayExpress database [13] under accession num-
ber E-MTAB-4696.
Real-time quantitative PCR (RT-qPCR)
Single-strand cDNA was synthesized from 1 μg total
RNA using the High Capacity RNA to cDNA Kit (Ap-
plied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions. RT-qPCR experiments
were carried out with a 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems). All reactions were per-
formed on 25 ng of cDNAs from BMEC and SCMEC
monolayers, BMVs, and SCMVs using the TaqMan
Fast Universal PCR Master Mix and different probes
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from the TaqMan Gene Expression Assays with the
following references:
Samples were run in duplicates on the same 96-well
plates and analyzed with the 7500 Software v2.0 (Applied
Biosystems). Relative expression levels were determined
according to the ΔΔCt method where the expression
level of the mRNA of interest is given by 2-ΔΔCT where
ΔΔCT = ΔCT target mRNA – ΔCT reference mRNA
(Gapdh for the MECs, Actb and Rpl13 for the MVs) in
the same sample.
Western blot analysis
The lysates (Lt) from BMEC monolayers (stimulated or
not with TNF-α), BMVs, and SCMVs were defrosted and
centrifuged at 13,000×g for clarification. Protein con-
centrations were determined using the Lowry method
(Bio-Rad, Hercules, CA, USA). After boiling, aliquots
containing equal amounts of protein were loaded in
Laemmli buffer and separated by 8.5 % sodium dodecyl
sulfate (SDS) polyacrylamide (Bio-Rad) gel electrophoresis
(PAGE) using a MiniBlot system (Bio-Rad). Proteins were
transferred onto nitrocellulose membranes (Amersham
Biosciences, Buckinghamshire, UK) in transfer buffer (Tris
25 mM, glycine 192 mM, ethanol 20 %). Membranes were
incubated overnight in blocking buffer at 4 °C and then
probed with primary antibodies diluted in blocking buffer
(TBS with milk 5 % and Tween20 0.2 %). The following
antibodies were used: goat anti-β-actin HRP 1/5000 (Santa
Cruz, Dallas, Texas, USA), mouse anti-claudin-5 2 μg/mL
(Life Technologies), rabbit anti-ZO-1 2 μg/mL (Life
Technologies), rabbit anti-occludin 2 μg/mL (Life
Technologies), rabbit anti-HOXA9 1.5 μg/mL (Novus
biological, Littleton, CO, USA), rabbit anti-HOXB7
0.5 μg/mL (Proteintech, Rosemont, IL, USA), rabbit anti-
TNFR1 0.5 μg/mL (Proteintech), and rabbit anti-TNFR2
0.5 μg/mL (Proteintech). After washing, membranes were
incubated with appropriate secondary horseradish perox-
idase (HRP)-conjugated IgG antibodies 1/2000 (Jackson
Immunoresearch). Finally, proteins were detected using a
chemiluminescence kit (Roche Diagnostics, Mannheim,
Germany) revealed with the G:Box chemi xx6 system
(Syngene, Cambridge, UK). Films were digitized using
GeneSys software (Syngene) and optical densities of the
bands were assessed using the NIH ImageJ software.
Design of the study and data analysis
For microarray-based transcriptomic analysis, two inserts
containing the BMEC or SCMEC monolayers, stimulated
or not with TNF-α 5 ng/mL for 12, 24, and 48 h, were
pooled for RNA isolation. The transcriptome analysis was
performed twice from independent in vitro BBB and BSCB
model preparations and TNF-α induction (duplicates).
For the basal differential gene expression analysis, the
ratio of the values in BMECs versus SCMECs or BMVs
versus SCMVs was filtered based on a fold change (FC)
≥1.45. For the differential gene expression analysis in
response to TNF-α, the values of the induction versus
control at the same time points were filtered based on
a FC ≥1.45 and <2 (genes moderately induced) or a FC
≥2 (genes highly induced). Only genes exhibiting the
defined FCs for all combinations between duplicates
were considered.
For BMEC or SCMEC analysis (RT-qPCR, ELISA,
western blot, permeability), at least three inserts (trip-
licates) containing the MEC monolayers were used
and all experiments were repeated at least three times
from independent in vitro BBB and BSCB model prep-
arations. All data are expressed as means ± standard
deviations. The values were compared using Student’s
t test. Results were considered statistically significant
at p ≤ 0.05 (*), p ≤ 0.01 (**), or p ≤ 0.001 (***). BMV and
SCMV analyses (RT-qPCR and western blot) were based
on three independent pools of at least six rats.
Transcript data mining
Biological interpretation of the transcriptomic data was
performed using the Java/Perl software PredictSearch®,
which has been previously described [14–16]. This soft-
ware characterizes the pathways and functional networks
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Results and discussion
Basal differential gene expression in BMECs and SCMECs
To identify genes that presented a distinct basal expres-
sion in BMECs and SCMECs, different criteria were ap-
plied on the transcriptomic data. Only values for all
controls higher than the background (according to Agilent
calculations) were considered. In a first approach, ratios
(BMEC values versus SCMEC) were filtered based on a
fold change (FC) ≥1.45. Only genes exhibiting the defined
FCs for all combinations between duplicates were consid-
ered. These criteria led to select 648 genes exhibiting a
higher expression in BMECs and 444 with a higher ex-
pression in SCMECs. Further analysis indicated that a high
number of genes encoding known endothelial markers
[17] and adhesion/TJ molecules have a similar expression
pattern in BMECs and SCMECs (Table 1). However, some
of the genes related to the extracellular matrix (ECM)
such as Bgn (biglycan), Col3a1 (collagen type III alpha 1),
Col1a1 (collagen type I alpha 1), Col1a2 (collagen type I
alpha 2), Slit3 (slit guidance ligand 3), Mgp (matrix Gla
protein), Spp1 (secreted phosphoprotein 1/osteopontin),
Ctgf (connective tissue growth factor), and Cldn9 (clau-
din-9) were among the most strongly expressed genes in
BMECs (Table 1). Other highly expressed BMEC genes
(data not shown) were related to either cellular messen-
gers within the central and peripheral nervous systems:
Gal (galanin), Geft (Rho guanine nucleotide exchange fac-
tor 25), Nsg1 (neuron specific gene family member 1), Npy
(neuropeptide Y); atherosclerosis: Ldb2 (LIM domain
binding 2), Xdh (xanthine dehydrogenase), Il1rl1/Il33r
(interleukin 1 receptor like 1); or fatty acid metabolism:
Lpl (lipoprotein lipase), and Apoe (apolipoprotein E).
Among the genes encoding growth factors, only Vegfc
(vascular endothelial growth factor C) and Tgfb2 (trans-
forming growth factor beta 2) exhibited a differential expres-
sion (Table 1). High basal expression of Tgfb2 in BMECs
might be correlated to the higher expression of TGF-β-
target genes such as Bgn, Ctgf, and collagens [18–20].
Thus, the transcriptomic analysis of SCMEC and
BMEC monolayers showed differential basal expression
of a significant number of genes indicative of phenotyp-
ical differences between these two CNS endothelial cell
types. Indeed, distinct and characteristic gene expression
profiles were found among blood vessels and MECs from
different tissues [21]. For instance, TGF-β2 was reported
to be higher in primary human cerebral endothelial cells
(HCECs) than in human umbilical vein endothelial cells
(HUVECs) at both mRNA and protein levels [22]. How-
ever, at this stage, we cannot exclude that the gene expres-
sion profile in BMECs and SCMECs resulted from the cell
culture conditions or a technical bias.
To investigate whether these differences at the basal
expression level exist also in vivo, RT-qPCR was per-
formed on RNA from freshly extracted BMVs and
SCMVs as the in vivo tissues closest to cultured MECs.
With the exception of Spp1, RT-qPCR confirmed the
differential expression observed in the transcriptomic
analysis for Bgn, Col3a1, Col1a2, Cldn9, Ctgf, and Tgfb2
(Table 2). Among these transcripts, Cldn9 exhibited the
strongest differential expression in vivo. Although the
functional impact of such a difference in Cldn9 basal ex-
pression between BMECs and SCMECs remains unclear,
the level of its expression in BMECs could reflect a
distinct degree of activation of signaling components.
Indeed, it was shown that silencing of c-Jun NH(2)-
terminal kinases (JNKs), JNK1 or JNK2, increased
CLDN9 mRNA expression in epithelial cells [23]. Thus,
it can be postulated that differential Cldn9 expression
might reflect different basal activities of JNKs in BMVs
and SCMVs, which consequently would impact the
barrier integrity through the modulation of claudins.
Table 1 Comparative basal expression of selected endothelium-
related genes in BMECs and SCMECs
Adhesion and ECM
molecules
Endothelial cell markers Growth factors
= > < = > < = > <
Cldn5 Cldn9 Itga2 Cd34 Cd248 Fabp5 Vegfa Vegfc
Cldn15 Ocln Cd93 Colec12 Vegfb Tgfb2
Esam Cadm1 Cd151 Klf4





















Ratio of the values in BMECs versus SCMECs was filtered by the following FCs.
FCs <1.45 and >0.69 correspond to a similar expression between BMECs and
SCMECs (=). FCs ≥1.45 correspond to a higher expression in BMECs (>). FCs
≤0.69 correspond to a higher expression in SCMECs (<)
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As shown in Fig. 1, we also observed differential expres-
sion of other genes such as Tnfrsf1b, Mmp9, Mmp13, and
to a lesser extent of Mmp14 in BMVs and SCMVs that
followed the expression pattern deduced from the tran-
scriptomic data in BMEC and SCMEC monolayers. In
contrast, RT-qPCR for Mmp3 and Mmp12 in BMVs and
SCMVs led to opposite values when compared to the tran-
scriptomic analysis (Fig. 1), which might illustrate differ-
ences between cultured MEC monolayers and freshly
extracted MVs.
Basal differential expression of the HOX gene family in
BMECs and SCMECs
The basal differences observed between BMECs and
SCMECs at the gene expression level suggested differen-
tial regulation of master program genes involved in cell
differentiation. Interestingly, among the top 50 genes
presenting higher expression in SCMECs than in BMECs,
Hoxa9 and Hoxb7 were listed in the first rank and these
results were confirmed using RT-qPCR (not shown).
Moreover, other members of the same family exhibited a
similar profile (Table 3). Similar differences were observed
in vivo when Hoxa9 and Hoxb7 expression was assessed
on mRNAs extracted from BMVs and SCMVs. Using RT-
qPCR, we found higher expression levels of Hoxa9 and
Hoxb7 mRNAs in SCMVs compared to BMVs (Table 3).
Western blot performed on protein extracts generated
from BMV and SCMV samples confirmed differential
expression of HOXA9 and HOXB7 at the protein level
(Fig. 2).
Hox genes encode transcriptional factors of the
homeobox (HOX) protein family. Expression of these
genes is involved in morphogenesis and differentiation
and is spatially and temporally regulated during em-
bryonic development. The role of HOXA9 is critical
for endothelium commitment resulting from the dif-
ferentiation of circulating endothelial progenitor cells
into mature endothelial cells [24]. On the other hand,
HOXB7 was reported to act as a key factor upregulating a
Table 2 In vivo validation of endothelium-related genes highly
expressed in BMECs compared to SCMECs
Gene Probe MA (in vitro) RT-qPCR (in vivo)
Bgn A_43_P11812 22.9 1.5
Col3a1 A_44_P146518 20.9 2.3
Col1a1 A_44_P238421 17.2 ND
Col1a2 A_43_P12783 13.6 1.9
Slit3 A_44_P1024315 12.8 ND
Mgp A_42_P588944 12.3 ND
Cldn9 A_44_P419898 10.0 46.2
Spp1 A_44_491796 4.9 0.5
Ctgf A_42_P484738 4.8 2.1
Tgfb2 A_44_P246538 2.5 1.9
Ratio of the values in BMEC versus SCMEC monolayers (MA microarray) and
freshly extracted BMVs versus SCMVs (RT-qPCR)
Fig. 1 In vivo validation of differentially expressed genes between brain and spinal cord MECs. Fold changes (FCs) deduced from ratios of
microarray (MA) values (BMEC versus SCMEC monolayers) were compared to FCs deduced from ratios of RT-qPCR values (freshly extracted
BMVs versus SCMVs)
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variety of pro-angiogenic stimuli leading to increased
matrix metalloproteinase-9 (MMP9) expression [25],
which is in line with its higher expression in SCMVs
(Fig. 2). Recently, a transcript analysis study revealed
shared and differential patterns of Hox gene expression
between endothelial cells from different vascular beds
[26]. Hoxd1, Hoxd3, Hoxd4, Hoxd8, and Hoxd9 were
found to be expressed at a higher level in blood-derived
outgrowth endothelial cells (BOECs) than in pulmonary
artery endothelial cells (PAECs). It was suggested that
the HOX clusters Hoxa7-10 and Hoxb5-7, which were
consistently expressed in BOECs, HUVECs, and human
aortic endothelial cells (HUAECs), remain expressed in
differentiated endothelial cells. In line with this study,
our results showing a differential expression in micro-
vessels of distinct vascular beds sustain the possibility
that Hox genes, known as master regulators of pos-
itional identity, can define endothelial phenotypes. It is
tempting to speculate that upstream epigenetic events,
which are known to regulate Hox gene expression [27],
are responsible for these different endothelial pheno-
types. Indeed, Hox gene expression during development
undergoes tight spatiotemporal regulation, partly by
chromatin structure and epigenetic factors [28]. Par-
ticularly, HOXA9 expression was found to be
downregulated by histone deacetylase (HDAC) inhibi-
tors while its overexpression partially rescued the endo-
thelial differentiation of adult progenitor cells blocked
by these inhibitors [29]. Although the impact of such
differences in Hox gene expression in SCMEC and
BMEC monolayers is unclear, it can be postulated that
they might influence the intrinsic capacity of MECs to
respond to external stimuli, such as pro-inflammatory
cytokines.
BMEC and SCMEC inflammatory responses
To investigate whether rat BMEC and SCMEC mono-
layers respond differently to pro-inflammatory cytokines,
they were either treated with TNF-α for 12, 24, and 48 h
or left untreated. Validation of the TNF-α response in
these cellular models was achieved by following expres-
sion and secretion of CCL2 in all tested conditions
(Fig. 3). RT-qPCR showed that the steady state levels of
CCL2 mRNA increased rapidly in BMECs after 12 h of
TNF-α treatment and then decreased progressively from
24 to 48 h (Fig. 3a). Although a similar TNF-α response
was observed in SCMECs, the level of induction at 12 h
was much lower than in BMECs. The inflammatory re-
sponse of BMECs and SCMECs to TNF-α was con-
firmed by measuring CCL2 protein levels in the culture
supernatants (Fig. 3b). TNF-α-induced secretion of CCL2
was maximal at 24 h in BMECs and at 48 h in SCMECs.
TJ proteins are essential in BBB homeostasis and among
them, occludin, ZO-1, and claudins in different vascular
beds show differential expression in development, path-
ology, and BBB demise [1]. Occludin immunostaining
in TNF-α-treated BMEC and SCMEC (not shown)
monolayers systematically showed decreased tight junc-
tion/pericellular distribution and cytoplasmic/vesicular-
like distribution compared to non-treated cells (Fig. 4a).
This altered distribution was not associated with overall
changes in occludin steady state levels as shown by
Table 3 Basal differential Hox gene expression in BMECs
compared to SCMECs
Gene Probe MA (in vitro) RT-qPCR (in vivo)
Hoxa9 A_44_P129029 0.04 0.002
Hoxa5 A_44_P292669 0.30 ND
Hoxb7 A_44_P266984 0.04 0.003
Hoxb9 A_44_P205783 0.60 ND
Hoxd9 A_44_P436218 0.20 ND
Ratio of the values in BMEC versus SCMEC monolayers (MA microarray) and
freshly extracted BMVs versus SCMVs (RT-qPCR)
Fig. 2 Differential protein expression of HOXA9 and HOXB7 in brain and spinal cord MECs. Western blot analysis (left panel) and quantification
(right panel) of HOXA9 and HOXB7 levels were performed in whole tissue lysates from freshly extracted BMVs and SCMVs. β-actin was used to
check loading of equal amounts of total protein. Quantification of the optical densities of each band was assessed using the NIH ImageJ software
and is shown in arbitrary units (AU). All data are representative of at least three experiments with superimposable results. Data are presented as
mean ± standard deviation (***p≤ 0.001)
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western blot analysis in BMEC monolayers (Fig. 4b).
Higher doses of TNF-α (100 ng/mL) on epithelial Caco-2
monolayers followed by western blot analysis have been
shown to decrease levels of phosphorylated occludin
(85 kDa), but had no effect on the non-phosphorylated
form (65 kDa) [30]. Our results suggest that the MEC
monolayers may express mainly the non-phosphorylated
form of occludin, with no effect of TNF-α on steady state
levels. In contrast, western blot analysis of claudin-5 and
ZO-1 (Fig. 4b) indicated decreased steady state levels of
these TJ proteins. Together, changes in occludin distribu-
tion and decreased claudin-5 and ZO-1 strongly suggested
disruption of MECs monolayer integrity by TNF-α. This
was confirmed by the increased Lucifer Yellow (LY) para-
cellular leakage in the abluminal compartment as shown
for the BMEC monolayer, (Fig. 4c), in agreement with pre-
vious studies [12, 31, 32].
Transcriptomic analysis of BMECs and SCMECs in
response to TNF-α
Transcriptomic analysis performed on rat MEC mono-
layers confirmed at the transcript level the decreased ex-
pression of Cldn5 (claudin-5) upon TNF-α treatment at
all time points in both BMECs and in SCMECs (Table 4).
Such a transcriptional repression of Cldn5 was reported
to be triggered via nuclear factor kappa B (NFkB) signal-
ing activity in retinal endothelial cells [33]. Like for
Cldn5, expression of Cldn9 was strongly repressed by
TNF-α in both BMECs and SCMECs at nearly all kinetic
time points (data not shown). This downregulation of
genes involved in TJ formation is likely associated with
the TNF-α-induced opening of the BBB.
Analysis of the overall transcriptomic data showed that
TNF-α induction was consistently more efficient in
BMECs and appeared earlier than in SCMECs (Fig. 5).
Indeed, in BMECs, the number of genes whose
expression was moderately induced by TNF-α (FC ≥1.45
and <2) reached a peak at 12 h, then decreased in the
course of time (Fig. 5a). Within the same FC range, the
maximal number of genes more strongly induced in
SCMECs was higher at 24 h, then decreased at 48 h but
remained slightly higher than that in BMECs (Fig. 5a). For
a FC ≥2, the number of induced genes increased from 12
to 24 h in SCMECs while it decreased in BMECs
(Fig. 5b). This differential induction might reflect either
the presence of cell-type specific TNF-α related signal-
ing factors or distinct basal activities of these factors in
BMECs and SCMECs.
To confirm the differential TNF-α response in BMECs
and SCMECs, we investigated the expression levels of
several known TNF-α targeted genes such as those en-
coding chemokines, including CCL2 and adhesion mole-
cules (ICAM1, VCAM1). Most of these genes exhibited
a stronger induction upon TNF-α treatment in BMECs
compared to SCMECs at 12 h while, except for Ccl5, the
opposite was true at 48 h in SCMECs (Table 5). Basal
expression of these genes was either similar in the two
cell types or higher in SCMECs (Table 5).
Remarkably, among the top ten genes with the highest
induction following TNF-α treatment at 12 h, in either
BMECs (Table 6(A)) or SCMECs (Table 6(B)), several
genes including Mmp3, Mmp9, Mmp10, Mmp12, and
Mmp13 that belong to the MMPs family were identified.
MMPs are important in development and in numerous
physiopathological processes including neuroinflamma-
tion. In the CNS, they cleave, activate, or release cytokines,
growth factors, receptors, and death-inducing ligands and
receptors through sheddase activity, and degrade compo-
nents of the basal lamina leading to disruption of the BBB
[34–36]. Most of the top ten genes exhibited a stronger
TNF-α response in BMECs and, with the exception of
Ass1 (argininosuccinate synthase), Ptgs2 (prostaglandin-
Fig. 3 CCL2 expression and secretion upon TNF-α at 12, 24, and 48 h in BMEC and SCMEC monolayers. a The steady state levels of Ccl2 mRNA
relative to Gapdh was assessed by RT-qPCR in all tested conditions. b CCL2 secretion in the culture supernatants was assessed by anti-CCL2 ELISA
quantification in all tested conditions. Data are presented as mean ± standard deviation (**p≤ 0.01; ***p≤ 0.001)
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endoperoxide synthase 2), and Ptges (prostaglandin E syn-
thase), a higher basal expression in SCMECs (Table 6).
Overall, our results indicate that TNF-α induced the
expression of similar sets of genes in BMECs and
SCMECs with, however, distinct efficiency and/or kinet-
ics. Such a finding in primary cell cultures is in line with
the generalized notion that responses of human MECs
(HMECs) and macrovascular human umbilical vein ECs
(HUVECs) to inflammatory molecules are basically com-
parable. Nevertheless, a considerable number of genes
could also be regulated in a distinct manner in different
EC types [37, 38] depending on the time points. It is
noteworthy to mention that most of these reports ana-
lyzing differential TNF-α induced gene expression in
Table 4 TNF-α modulated expression of genes encoding TJ






Gene Probe 12 h 24 h 48 h 12 h 24 h 48 h
Ocln (a) A_43_P12552 1.7 0.7 0.5 0.5 0.5 0.6 0.9
Ocln (b) A_44_P1007729 1.7 0.8 0.5 0.7 0.5 0.7 1.0
Cldn5 A_43_P15791 0.8 0.5 0.5 0.4 0.6 0.4 0.4
Ratio of the values in BMECs versus SCMECs and in TNF-α treated cultures after
12, 24, and 48 h versus non-treated cultures were filtered for FC ≥1.45 (in bold)
or FC ≤0.69 (in bold and in italic)
Fig. 4 TNF-α effects on MEC monolayers integrity (24 h incubation). a Representative photomicrographs of BMEC monolayers fixed, permeabilized,
and stained with an antibody directed against occludin (scale bars, 10 μm). Nuclei are stained with Hoechst. Arrows indicate pericellular localization of
TJ protein occludin, while arrowheads point to cytoplasmic/vesicular of occludin. Note the decreased pericellular and increased cytoplasmic/vesicular
distribution of occludin upon TNF-α treatment. b Western blot analysis (left panel) and quantification (right panel) of TJ proteins ZO-1, occludin, and
claudin-5 levels were performed in whole tissue lysates from BMEC monolayers. Quantification of the optical densities of each band was assessed using
the NIH ImageJ software. Values deduced from non-treated cultures (Ctrl) were considered as 100 %. c Barrier integrity was assessed by quantification
of the Lucifer Yellow (LY) endothelial permeability, Pe(LY). The loss of barrier integrity was validated for Pe(LY) above 0.6.10
−3 cm/min. All data
are representative of at least three experiments with similar results and are presented as means ± standard deviation (**p ≤ 0.01; ***p ≤ 0.001)
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ECs were performed for an incubation period not ex-
ceeding 12 h. As mentioned above, one possibility is that
basal expression or activity levels of signal transducers
might impact the level or the delay of the TNF-α re-
sponse in BMECs and SCMECs.
TNF-α-induced expression of Tnfrsf1b is restricted to
SCMECs
To investigate whether the delay of response in BMECs
and SCMECs was correlated with differences in TNF
signaling, we assessed whether genes encoding known
factors involved in this pathway were modulated. Inter-
estingly, while a slight difference was observed between
BMECs and SCMECs for Tnfrsf1a encoding TNFR1/p55,
expression of Tnfrsf1b encoding TNFR2/p75 was higher in
BMECs compared to SCMECs (Table 7). Western blots
performed on protein extracts generated from freshly ex-
tracted BMV and SCMV samples confirmed higher
TNFR1 and TNFR2 protein levels (2.3- and 2.8-fold, re-
spectively) in BMVs (Fig. 6). However, no difference was
observed for genes encoding other TNF-related receptor
members or products involved in the TNF signaling
Fig. 5 Kinetics of global transcriptomic effects of TNF-α in BMEC and SCMEC monolayers. Genes moderately induced and highly induced upon
TNF-α treatment at either 12, 24, or 48 h were selected according to their FCs (a 1.45 ≤ FC < 2 and b FC ≥ 2, respectively)






Gene Probe 12 h 24 h 48 h 12 h 24 h 48 h
Ccl2 (a) A_42_P695401 0.6 7.4 4.8 2.2 3.5 3.5 3.1
Ccl2 (b) A_42_P695407 0.6 5.7 2.1 2.1 4.7 3.8 3.5
Ccl7 (a) A_44_P1022002 0.3 11.0 6.7 3.0 5.4 4.4 3.9
Ccl7 (b) A_44_P391296 0.3 14.0 6.2 2.8 5.5 5.0 4.5
Ccl5 A_44_P304323 0.2 7.8 11.0 16.7 6.5 7.7 8.0
Cxcl1 A_42_P473398 0.8 2.5 2.2 1.2 2.0 1.8 1.8
Cxcl2 A_44_P5151976 0.7 4.4 3.3 1.4 2.4 2.6 2.5
Cxcl3 A_44_P363116 0.5 9.8 7.5 2.7 6.1 5.0 3.9
Cxcl6 A_44_P270366 0.5 7.6 4.4 4.3 2.2 5.5 6.6
Cxcl10 A_44_P1039128 0.7 2.2 1.1 1.4 1.5 2.6 2.1
Cxcl11 A_44_P175495 0.4 8.6 7.8 5.6 5.9 8.9 6.4
Cxcl12 (a) A_44_P337351 0.9 3.1 2.7 0.8 3.2 2.7 2.0
Cxcl12 (b) A_44_P1034439 1.1 3.5 1.3 0.9 2.5 2.4 2.1
Icam1 A_43_P15253 0.8 3.0 3.4 0.8 2.0 3.8 2.3
Vcam1 A_42_P499158 1.0 7.7 2.0 1.4 3.0 2.4 2.3
Ratio of the values in BMECs versus SCMECs and in TNF-α treated cultures after 12, 24, and 48 h versus non-treated cultures were filtered for FC ≥1.45 (in bold) or
FC ≤0.69 (in bold and in italic)
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pathway such as Birc2 (protein: c-IAP1), Birc3 (protein: c-
IAP2), Tradd, Traff-2/3, Rela, Nfkb-1/2, Nfkbi-a/b, Ikbkb,
Jun, Junb, and Jund (Additional file 1: Table S1). Among
all genes encoding TNF-α receptors, Tnfrsf11b was signifi-
cantly induced by TNF-α at all time points in BMECs and
at 24 and 48 h in SCMECs, while Tnfrsf1b was induced at
24 and 48 h in SCMECs but not in BMECs (Table 7).
TNFR1 and TNFR2 elicit distinct features [39]. Soluble
TNF (sTNF) only activates TNFR1, while membrane-
bound TNF (mTNF) activates both receptors [40, 41]. In
contrast to TNFR1 expressed in nearly all cells, TNFR2,
which can be recognized by both TNF-α and LTA (TNF-β)
ligands, is limited to some cell types including endothelial
cells [42]. TNFR1 and TNFR2 subunits form a hetero-
complex leading to NFkB/MAPK and NFkB/PI3K-AKT-
dependent NFkB/JNK signaling pathways, respectively,
which trigger distinct impacts on apoptosis, proliferation,
and survival [43–46]. On the other hand, it was postulated
that the observed variability in TNF-induced CXCR3 che-
mokine expression in different microvascular beds might
depend on the endothelial TNFR2 expression according to
distinct anatomic loci [47].
Thus, one may speculate that the relative higher
abundance of TNF-α receptors in BMECs compared to
SCMECs could trigger a more rapid and stronger TNF-α
response. In contrast to BMECs, SCMECs could require
Table 6 TNF-α modulated expression of the top ten upregulated genes in BMECs (A) and SCMECs (B)
A Basal TNF-α
BMEC vs SCMEC BMEC SCMEC
Gene Probe 12 h 24 h 48 h 12 h 24 h 48 h
Mmp3 A_44_P318318 0.4 34.9 9.1 3.1 7.1 7.0 5.1
Mmp12 A_44_P555271 0.2 33.6 25.6 7.6 6.6 6.9 6.5
Mmp13 A_42_P606126 0.2 31.4 8.8 2.4 5.7 2.9 3.1
Mmp10 A_44_P404861 0.2 16.5 8.8 10.0 6.9 8.3 9.7
Cd69 A_43_P16166 0.5 14.7 11.6 3.2 8.4 6.7 4.8
Ubd A_42_P602724 0.5 14.6 10.1 8.7 4.2 7.4 5.0
Ccl7 A_44_P391296 0.3 13.6 6.2 2.8 5.5 5.0 4.5
Ass1 A_44_P391296 1.6 13.3 14.5 5.2 7.9 9.2 7.4
Ptgs2 A_44_P472989 1.0 12.5 10.7 2.9 5.2 6.5 3.6
Mmp9 A_42_P606126 0.3 12.1 22.2 22.6 6.4 5.2 7.5
B Basal TNF-α
BMEC vs SCMEC SCMEC BMEC
Gene Probe 12 h 24 h 48 h 12 h 24 h 48 h
Mmp9 A_44_P501112 0.5 10.2 7.9 9.9 11.7 20.6 17.6
Cd69 A_43_P16166 0.5 8.4 6.7 4.8 14.7 11.6 3.2
Ass1 A_44_P391296 1.6 7.9 9.2 7.4 13.3 14.5 5.2
Ptges A_43_P12079 1.1 7.3 5.9 4.9 7.2 6.1 4.3
Mmp3 A_44_P318318 0.4 7.1 7.0 5.1 34.9 9.1 3.1
Mmp10 A_44_P404861 0.2 6.9 8.3 9.7 16.5 8.8 10.0
Mmp12 A_44_P555271 0.2 6.6 6.9 6.5 33.6 25.6 7.6
Ccl5 A_44_P304323 0.2 6.5 7.7 8.0 7.8 11.0 16.7
Cxcl3 A_44_P363116 0.5 6.1 5.0 3.9 9.8 7.5 2.7
Cxcl11 A_44_P175495 0.4 5.9 8.9 6.4 8.6 7.8 5.6
Ratio of the values in BMECs versus SCMECs and in TNF-α treated cultures after 12, 24, and 48 h versus non-treated cultures were filtered for FC ≥1.45 (in bold) or
FC ≤0.69 (in bold and in italic)
Table 7 TNF-α modulated expression of TNF-α receptor genes






Gene Probe 12 h 24 h 48 h 12 h 24 h 48 h
Tnfrsf1a A_43_P15259 1.5 0.6 0.6 0.9 0.8 0.9 0.7
Tnfrsf1b A_43_P533794 3.1 1.3 0.6 1.1 1.4 2.8 2.3
Tnfrsf11b A_44_P458021 0.9 4.4 2.4 2.3 1.4 2.9 2.9
Ratio of the values in BMECs versus SCMECs and in TNF-α treated cultures after
12, 24, and 48 h versus non-treated cultures were filtered for FC ≥1.45 (in bold)
or FC ≤0.69 (in bold and in italic)
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the TNF induction of at least Tnfrsf1b expression to elicit
a full, albeit delayed, TNF-α response.
Noteworthy, only two other genes, Tgfb2 and Prkcb,
exhibited an expression pattern similar to Tnfrsf1b, which
is higher in BMECs vs SCMECs (2.5- and 2.3-fold, re-
spectively) and induced 2.5-fold by TNF-α at 24 and 48 h
in SCMECs (not shown). It is likely that the higher basal
expression of Prkcb in BMECs sustained the stronger and
earlier TNF-α response in these cells since this gene en-
codes protein kinase Cβ, which plays a major role in TNF-
α-induced human vascular endothelial cell apoptosis [48].
Conclusions
The main finding of this study supports the idea that the
Hox gene expression pattern termed in a recent report the
“HOX code” [26] can define distinct endothelial pheno-
types. Indeed, our data demonstrate that at least HOXA9
and HOXB7 were more abundant at the mRNA and pro-
tein levels in MECs and freshly extracted MVs from the
spinal cord than those from the brain. In addition to its
critical role for endothelial commitment during progenitor
cell maturation [24], HOXA9 might be involved in main-
taining a specific differentiation status in mature ECs
through its control of the basal expression of its gene tar-
gets. In turn, HOXB7 was shown to act as a key factor to
upregulate a variety of pro-angiogenic stimuli [25]. Al-
though the impact of distinct levels of these factors in
BMVs and SCMVs remains to be elucidated, it is tempting
to speculate that they may control the EC response to ex-
ternal stimuli such as the TNF response. For instance, the
involvement of HOXA9 in maintaining ECs in a “basal”
state along with its inhibitory effect on NFkB-dependent
transcriptional activation of endothelium has been re-
ported [49]. Thus, while low HOXA9 abundance in
BMECs might account for a sustained TNF response, its
higher level in SCMECs would impair this response at an
early stage, explaining the distinct efficiency and kinetics
of the TNF response observed in the two cell types. At
later stages, the TNF induction of Tnfrsf1b, specifically in
SCMECs, may allow a full TNF response.
Overall our work highlights that basal gene expression
is differentially regulated within ECs depending on dis-
tinct vascular beds and may account for different re-
sponses to inflammatory mediators. It can be expected
that the identification of these mechanisms and the
resulting functions will allow improvement of models for
vascular development and plasticity as well as manipula-
tion of EC phenotypes for therapeutic applications.
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Additional file 1: Table S1. TNF-α modulated expression of genes
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